Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102804 · ClinicalTrials.gov registry record · Phase 3
Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 663
- Enrollment target
NCT00102804 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 663 participants.
The verdict
NCT00102804, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 663 participants
- Enrollment target
Study Summary
This study is a randomized Phase 3, double-blind study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care in NSCLC. Participants must have received 1 of 6 induction regimens for 4 cycles and did not have progressive disease prior to randomization (enrollment) into this trial.
Interventions
- DRUG Placebo
- DRUG Pemetrexed
- OTHER Best Supportive Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 663 participants |
| Start Date | 2005-03 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00102804
The ClinicalTrials.gov registry entry for NCT00102804 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 663 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00102804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00102804 about?
NCT00102804 is a clinical study titled "Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)". This study is a randomized Phase 3, double-blind study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care in NSCLC. Participants must have received 1 of 6 induction regimens for 4 cycles and did not have progressive disease prior to randomization (enrollment...
What is the current status of trial NCT00102804?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 663 participants. The study started on 2005-03. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00102804?
The interventions under investigation include: Placebo (DRUG), Pemetrexed (DRUG), Best Supportive Care (OTHER).
Who is sponsoring clinical trial NCT00102804?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.